Literature DB >> 2918325

Survival in multiple sclerosis.

S Poser1, J F Kurtzke, W Poser, G Schlaf.   

Abstract

Survival from onset of symptoms was calculated for two series of MS patients, a population-based epidemiologic series from southern Lower Saxony of 224 cases, and a revised hospital series of 1429 cases from 11 neurologic centers throughout the Federal Republic of Germany. Median survival for the epidemiologic series was 35-42 years, with no finer estimate possible. Observed survival was 3/5 expected survival after 35 years of illness. Survival in this series was similar to that from two other population-based reports. No significant difference was found between the sexes, though patients with onset at age 35 + had a significantly shorter survival than those with onset at age under 35 years. The much larger hospital series, where median survival was 30 years, demonstrated significant differences separately favoring females and young onsets. However, the ratios of observed to expected survival from population life tables were strikingly similar among all four subgroups defined by sex and age at onset. While overall there is a substantial reduction in the expectation of life in MS, the differential survival by sex and age appears to be a reflection of the expected survival by sex and age per se, and not that of the disease.

Entities:  

Mesh:

Year:  1989        PMID: 2918325     DOI: 10.1016/0895-4356(89)90089-9

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  9 in total

1.  Prognostic criteria in an epidemiological group of patients with multiple sclerosis: an exploratory study.

Authors:  K Lauer; W Firnhaber
Journal:  J Neurol       Date:  1992-02       Impact factor: 4.849

2.  Suicide and multiple sclerosis: an epidemiological investigation.

Authors:  E N Stenager; E Stenager; N Koch-Henriksen; H Brønnum-Hansen; K Hyllested; K Jensen; U Bille-Brahe
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-07       Impact factor: 10.154

3.  Utilisation and cost of professional care and assistance according to disability of patients with multiple sclerosis in Flanders (Belgium)

Authors:  H Carton; R Loos; J Pacolet; K Versieck; R Vlietinck
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-04       Impact factor: 10.154

4.  The natural history of multiple sclerosis: a regional study with some longitudinal data.

Authors:  D H Miller; R W Hornabrook; G Purdie
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-05       Impact factor: 10.154

5.  Economic evaluation of multiple sclerosis in the UK, Germany and France.

Authors:  N Murphy; C Confavreux; J Haas; N König; E Roullet; M Sailer; M Swash; C Young; J L Mérot
Journal:  Pharmacoeconomics       Date:  1998-05       Impact factor: 4.981

6.  Treating relapsing multiple sclerosis with subcutaneous versus intramuscular interferon-beta-1a: modelling the clinical and economic implications.

Authors:  Shien Guo; Duygu Bozkaya; Alexandra Ward; Judith A O'Brien; Khajak Ishak; Randy Bennett; Ahmad Al-Sabbagh; Dennis M Meletiche
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

7.  Impact of disease-modifying therapies on the survival of patients with multiple sclerosis in Taiwan, 1997-2008.

Authors:  Ching-Piao Tsai; Charles Tzu-Chi Lee
Journal:  Clin Drug Investig       Date:  2013-09       Impact factor: 2.859

8.  Prognostic factors for survival in multiple sclerosis: a longitudinal, population based study in Møre and Romsdal, Norway.

Authors:  R Midgard; G Albrektsen; T Riise; G Kvåle; H Nyland
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-04       Impact factor: 10.154

9.  Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study.

Authors:  Emmanuelle Leray; Sandra Vukusic; Marc Debouverie; Michel Clanet; Bruno Brochet; Jérôme de Sèze; Hélène Zéphir; Gilles Defer; Christine Lebrun-Frenay; Thibault Moreau; Pierre Clavelou; Jean Pelletier; Eric Berger; Philippe Cabre; Jean-Philippe Camdessanché; Shoshannah Kalson-Ray; Christian Confavreux; Gilles Edan
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.